Skip to main content
Premium Trial:

Request an Annual Quote

Dotz Nano Inks Southeast Asia Distribution Deals for Point-of-Care SARS-CoV-2 Test Platform

NEW YORK — Dotz Nano said on Thursday that it has signed two new distribution deals for Southeast Asia for its point-of-care SARS-CoV-2 testing platform.

The Dotz Mega-Diagnostic Platform includes assay kits, an integrated diagnostic instrument, and a results management system, and uses RT-LAMP to detect the virus in nasopharyngeal swab and saliva samples. It can simultaneously test up to 96 samples, providing results within 30 minutes, according to Dotz. The platform is CE-IVD marked and has been submitted for Emergency Use Authorization with the US Food and Drug Administration.

Under the terms of the deals, ScienceVision will distribute the platform in Malaysia and World Siam Group will distribute it in Thailand. Additional terms were not disclosed.

"The Southeast Asian region is a very important market for us, where we expect significant growth for our COVID-19 diagnostic solution," Dotz CEO Gideon Shmuel said in a statement. "Given the companies' deep connections, infrastructure, and experience in this area, our partnerships will also ensure that our local customers are provided with the best service and support."

In addition to SARS-CoV-2, Israel-based Dotz is evaluating launching diagnostic kits for influenza and other viruses including Lassa, dengue, and Zika.